{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:31:09Z","timestamp":1790857869461,"version":"4.1.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,11,28]],"date-time":"2017-11-28T00:00:00Z","timestamp":1511827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,11,28]],"date-time":"2017-11-28T00:00:00Z","timestamp":1511827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mutations in E3 ubiquitin ligase Parkin have been linked to familial Parkinson\u2019s disease. Accumulating evidence suggests that Parkin is a tumor suppressor, but the underlying mechanism is poorly understood. Here we show that Parkin is an E3 ubiquitin ligase for hypoxia-inducible factor 1\u03b1 (HIF-1\u03b1). Parkin interacts with HIF-1\u03b1 and promotes HIF-1\u03b1 degradation through ubiquitination, which in turn inhibits metastasis of breast cancer cells. Parkin downregulation in breast cancer cells promotes metastasis, which can be inhibited by targeting HIF-1\u03b1 with RNA interference or the small-molecule inhibitor YC-1. We further identify lysine 477 (K477) of HIF-1\u03b1 as a major ubiquitination site for Parkin. K477R HIF-1\u03b1 mutation and specific cancer-associated Parkin mutations largely abolish the functions of Parkin to ubiquitinate HIF-1\u03b1 and inhibit cancer metastasis. Importantly, Parkin expression is inversely correlated with HIF-1\u03b1 expression and metastasis in breast cancer. Our results reveal an important mechanism for Parkin in tumor suppression and HIF-1\u03b1 regulation.<\/jats:p>","DOI":"10.1038\/s41467-017-01947-w","type":"journal-article","created":{"date-parts":[[2017,11,22]],"date-time":"2017-11-22T14:46:50Z","timestamp":1511362010000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":200,"title":["Parkin targets HIF-1\u03b1 for ubiquitination and degradation to inhibit breast tumor progression"],"prefix":"10.1038","volume":"8","author":[{"given":"Juan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuetian","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Tomsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christen A.","family":"Khella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Gatza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dajing","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce G.","family":"Haffty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohui","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,28]]},"reference":[{"key":"1947_CR1","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1056\/NEJM200005253422103","volume":"342","author":"CB Lucking","year":"2000","unstructured":"Lucking, C. B. et al. Association between early-onset Parkinson\u2019s disease and mutations in the parkin gene. N. Engl. J. Med. \n                           342, 1560\u20131567 (2000).","journal-title":"N. Engl. J. Med."},{"key":"1947_CR2","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.neuron.2014.12.007","volume":"85","author":"AM Pickrell","year":"2015","unstructured":"Pickrell, A. M. & Youle, R. J. The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson\u2019s disease. Neuron \n                           85, 257\u2013273 (2015).","journal-title":"Neuron"},{"key":"1947_CR3","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.tcb.2014.01.001","volume":"24","author":"KF Winklhofer","year":"2014","unstructured":"Winklhofer, K. F. Parkin and mitochondrial quality control: toward assembling the puzzle. Trends Cell Biol. \n                           24, 332\u2013341 (2014).","journal-title":"Trends Cell Biol."},{"key":"1947_CR4","doi-asserted-by":"publisher","first-page":"13354","DOI":"10.1073\/pnas.240347797","volume":"97","author":"Y Zhang","year":"2000","unstructured":"Zhang, Y. et al. Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc. Natl Acad. Sci. USA \n                           97, 13354\u201313359 (2000).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1947_CR5","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S1097-2765(02)00583-X","volume":"10","author":"Y Imai","year":"2002","unstructured":"Imai, Y. et al. CHIP is associated with Parkin, a gene responsible for familial Parkinson\u2019s disease, and enhances its ubiquitin ligase activity. Mol. Cell \n                           10, 55\u201367 (2002).","journal-title":"Mol. Cell"},{"key":"1947_CR6","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/nm1001-1144","volume":"7","author":"KK Chung","year":"2001","unstructured":"Chung, K. K. et al. Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nat. Med. \n                           7, 1144\u20131150 (2001).","journal-title":"Nat. Med."},{"key":"1947_CR7","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1126\/science.1060627","volume":"293","author":"H Shimura","year":"2001","unstructured":"Shimura, H. et al. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson\u2019s disease. Science \n                           293, 263\u2013269 (2001).","journal-title":"Science"},{"key":"1947_CR8","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/77060","volume":"25","author":"H Shimura","year":"2000","unstructured":"Shimura, H. et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nature Genetics \n                           25, 302\u2013305 (2000).","journal-title":"Nature genetics"},{"key":"1947_CR9","doi-asserted-by":"publisher","first-page":"5956","DOI":"10.1073\/pnas.0931262100","volume":"100","author":"R Cesari","year":"2003","unstructured":"Cesari, R. et al. Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. Proc. Natl Acad. Sci. USA \n                           100, 5956\u20135961 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1947_CR10","doi-asserted-by":"publisher","first-page":"6002","DOI":"10.1038\/onc.2008.199","volume":"27","author":"M Fujiwara","year":"2008","unstructured":"Fujiwara, M. et al. Parkin as a tumor suppressor gene for hepatocellular carcinoma. Oncogene \n                           27, 6002\u20136011 (2008).","journal-title":"Oncogene"},{"key":"1947_CR11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.molcel.2015.08.011","volume":"60","author":"SB Lee","year":"2015","unstructured":"Lee, S. B. et al. Parkin regulates mitosis and genomic stability through Cdc20\/Cdh1. Mol. Cell \n                           60, 21\u201334 (2015).","journal-title":"Mol. Cell"},{"key":"1947_CR12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00109-013-1107-0","volume":"92","author":"L Xu","year":"2014","unstructured":"Xu, L., Lin, D. C., Yin, D. & Koeffler, H. P. An emerging role of PARK2 in cancer. J Mol. Med. \n                           92, 31\u201342 (2014).","journal-title":"J Mol. Med."},{"key":"1947_CR13","doi-asserted-by":"publisher","first-page":"15145","DOI":"10.1073\/pnas.1009941107","volume":"107","author":"G Poulogiannis","year":"2010","unstructured":"Poulogiannis, G. et al. PARK2 deletions occur frequently in sporadic colorectal cancer and accelerate adenoma development in Apc mutant mice. Proc. Natl Acad. Sci. USA \n                           107, 15145\u201315150 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1947_CR14","doi-asserted-by":"publisher","first-page":"8370","DOI":"10.1038\/sj.onc.1207072","volume":"22","author":"SR Denison","year":"2003","unstructured":"Denison, S. R. et al. Alterations in the common fragile site gene Parkin in ovarian and other cancers. Oncogene \n                           22, 8370\u20138378 (2003).","journal-title":"Oncogene"},{"key":"1947_CR15","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1158\/1078-0432.CCR-03-0086","volume":"10","author":"MC Picchio","year":"2004","unstructured":"Picchio, M. C. et al. Alterations of the tumor suppressor gene Parkin in non-small cell lung cancer. Clin. Cancer Res. \n                           10, 2720\u20132724 (2004).","journal-title":"Clin. Cancer Res."},{"key":"1947_CR16","doi-asserted-by":"publisher","first-page":"29231","DOI":"10.1074\/jbc.M110.108241","volume":"285","author":"SP Tay","year":"2010","unstructured":"Tay, S. P. et al. Parkin enhances the expression of cyclin-dependent kinase 6 and negatively regulates the proliferation of breast cancer cells. J. Biol. Chem. \n                           285, 29231\u201329238 (2010).","journal-title":"J. Biol. Chem."},{"key":"1947_CR17","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s12253-012-9591-z","volume":"19","author":"EM Je","year":"2013","unstructured":"Je, E. M., Yoo, N. J. & Lee, S. H. Somatic mutation of PARK2 tumor suppressor gene is not common in common solid cancers. Pathol. Oncol. Res. \n                           19, 393\u2013395 (2013).","journal-title":"Pathol. Oncol. Res."},{"key":"1947_CR18","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. \n                           2, 401\u2013404 (2012).","journal-title":"Cancer Discov."},{"key":"1947_CR19","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/ng.491","volume":"42","author":"S Veeriah","year":"2010","unstructured":"Veeriah, S. et al. Somatic mutations of the Parkinson\u2019s disease-associated gene PARK2 in glioblastoma and other human malignancies. Nat. Genet. \n                           42, 77\u201382 (2010).","journal-title":"Nat. Genet."},{"key":"1947_CR20","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/ncb3330","volume":"18","author":"EL LaGory","year":"2016","unstructured":"LaGory, E. L. & Giaccia, A. J. The ever-expanding role of HIF in tumour and stromal biology. Nat. Cell Biol. \n                           18, 356\u2013365 (2016).","journal-title":"Nat. Cell Biol."},{"key":"1947_CR21","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.cell.2012.01.021","volume":"148","author":"GL Semenza","year":"2012","unstructured":"Semenza, G. L. Hypoxia-inducible factors in physiology and medicine. Cell \n                           148, 399\u2013408 (2012).","journal-title":"Cell"},{"key":"1947_CR22","doi-asserted-by":"publisher","first-page":"7081","DOI":"10.1128\/MCB.00773-08","volume":"28","author":"MY Koh","year":"2008","unstructured":"Koh, M. Y., Darnay, B. G. & Powis, G. Hypoxia-associated factor, a novel E3-ubiquitin ligase, binds and ubiquitinates hypoxia-inducible factor 1alpha, leading to its oxygen-independent degradation. Mol. Cell Biol. \n                           28, 7081\u20137095 (2008).","journal-title":"Mol. Cell Biol."},{"key":"1947_CR23","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/nature11207","volume":"487","author":"M Montagner","year":"2012","unstructured":"Montagner, M. et al. SHARP1 suppresses breast cancer metastasis by promoting degradation of hypoxia-inducible factors. Nature \n                           487, 380\u2013384 (2012).","journal-title":"Nature"},{"key":"1947_CR24","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/nature12043","volume":"496","author":"SA Sarraf","year":"2013","unstructured":"Sarraf, S. A. et al. Landscape of the PARKIN-dependent ubiquitylome in response to mitochondrial depolarization. Nature \n                           496, 372\u2013376 (2013).","journal-title":"Nature"},{"key":"1947_CR25","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00441-015-2340-3","volume":"364","author":"G Maugeri","year":"2016","unstructured":"Maugeri, G. et al. Parkin modulates expression of HIF-1alpha and HIF-3alpha during hypoxia in gliobastoma-derived cell lines in vitro. Cell Tissue Res. \n                           364, 465\u2013474 (2016).","journal-title":"Cell Tissue Res."},{"key":"1947_CR26","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. \n                           6, pl1 (2013).","journal-title":"Sci. Signal."},{"key":"1947_CR27","doi-asserted-by":"publisher","first-page":"e82241","DOI":"10.1371\/journal.pone.0082241","volume":"8","author":"B Gyorffy","year":"2013","unstructured":"Gyorffy, B., Surowiak, P., Budczies, J. & Lanczky, A. Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS ONE \n                           8, e82241 (2013).","journal-title":"PLoS ONE"},{"key":"1947_CR28","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/sj.embor.embor764","volume":"4","author":"E Sakata","year":"2003","unstructured":"Sakata, E. et al. Parkin binds the Rpn10 subunit of 26S proteasomes through its ubiquitin-like domain. EMBO Rep. \n                           4, 301\u2013306 (2003).","journal-title":"EMBO Rep."},{"key":"1947_CR29","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1111\/j.1471-4159.2008.05261.x","volume":"105","author":"DJ Moore","year":"2008","unstructured":"Moore, D. J., West, A. B., Dikeman, D. A., Dawson, V. L. & Dawson, T. M. Parkin mediates the degradation-independent ubiquitination of Hsp70. J. Neurochem. \n                           105, 1806\u20131819 (2008).","journal-title":"J. Neurochem."},{"key":"1947_CR30","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1523\/JNEUROSCI.23-08-03316.2003","volume":"23","author":"Y Ren","year":"2003","unstructured":"Ren, Y., Zhao, J. & Feng, J. Parkin binds to alpha\/beta tubulin and increases their ubiquitination and degradation. J. Neurosci. \n                           23, 3316\u20133324 (2003).","journal-title":"J. Neurosci."},{"key":"1947_CR31","doi-asserted-by":"publisher","first-page":"16259","DOI":"10.1073\/pnas.1113884108","volume":"108","author":"C Zhang","year":"2011","unstructured":"Zhang, C. et al. Parkin, a p53 target gene, mediates the role of p53 in glucose metabolism and the Warburg effect. Proc. Natl Acad. Sci. USA \n                           108, 16259\u201316264 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1947_CR32","doi-asserted-by":"publisher","first-page":"3701","DOI":"10.1172\/JCI44736","volume":"121","author":"KY Kim","year":"2011","unstructured":"Kim, K. Y. et al. Parkin is a lipid-responsive regulator of fat uptake in mice and mutant human cells. J. Clin. Invest. \n                           121, 3701\u20133712 (2011).","journal-title":"J. Clin. Invest."},{"key":"1947_CR33","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1093\/jmcb\/mjt003","volume":"5","author":"E Duplan","year":"2013","unstructured":"Duplan, E. et al. Parkin differently regulates presenilin-1 and presenilin-2 functions by direct control of their promoter transcription. J. Mol. Cell Biol. \n                           5, 132\u2013142 (2013).","journal-title":"J. Mol. Cell Biol."},{"key":"1947_CR34","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s11033-005-3961-5","volume":"33","author":"PG Unschuld","year":"2006","unstructured":"Unschuld, P. G. et al. Parkin modulates gene expression in control and ceramide-treated PC12 cells. Mol. Biol. Rep. \n                           33, 13\u201332 (2006).","journal-title":"Mol. Biol. Rep."},{"key":"1947_CR35","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/20459","volume":"399","author":"PH Maxwell","year":"1999","unstructured":"Maxwell, P. H. et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature \n                           399, 271\u2013275 (1999).","journal-title":"Nature"},{"key":"1947_CR36","doi-asserted-by":"publisher","first-page":"4406","DOI":"10.18632\/oncotarget.3017","volume":"6","author":"L Wu","year":"2015","unstructured":"Wu, L. et al. HIF-2alpha mediates hypoxia-induced LIF expression in human colorectal cancer cells. Oncotarget \n                           6, 4406\u20134417 (2015).","journal-title":"Oncotarget"},{"key":"1947_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms2982","volume":"4","author":"BE Riley","year":"2013","unstructured":"Riley, B. E. et al. Structure and function of Parkin E3 ubiquitin ligase reveals aspects of RING and HECT ligases. Nat. Commun. \n                           4, 1982 (2013).","journal-title":"Nat. Commun."},{"key":"1947_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms2983","volume":"4","author":"DE Spratt","year":"2013","unstructured":"Spratt, D. E. et al. A molecular explanation for the recessive nature of parkin-linked Parkinson\u2019s disease. Nat. Commun. \n                           4, 1983 (2013).","journal-title":"Nat. Commun."},{"key":"1947_CR39","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1158\/0008-5472.CAN-14-1433","volume":"75","author":"DC Lin","year":"2015","unstructured":"Lin, D. C. et al. Genomic and functional analysis of the E3 Ligase PARK2 in glioma. Cancer Res. \n                           75, 1815\u20131827 (2015).","journal-title":"Cancer Res."},{"key":"1947_CR40","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1038\/emboj.2011.204","volume":"30","author":"VK Chaugule","year":"2011","unstructured":"Chaugule, V. K. et al. Autoregulation of Parkin activity through its ubiquitin-like domain. The EMBO J. \n                           30, 2853\u20132867 (2011).","journal-title":"The EMBO J."},{"key":"1947_CR41","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1126\/science.1237908","volume":"340","author":"JF Trempe","year":"2013","unstructured":"Trempe, J. F. et al. Structure of parkin reveals mechanisms for ubiquitin ligase activation. Science \n                           340, 1451\u20131455 (2013).","journal-title":"Science"},{"key":"1947_CR42","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/sj.embor.7400188","volume":"5","author":"PJ Kahle","year":"2004","unstructured":"Kahle, P. J. & Haass, C. How does parkin ligate ubiquitin to Parkinson\u2019s disease? EMBO Rep. \n                           5, 681\u2013685 (2004).","journal-title":"EMBO Rep."},{"key":"1947_CR43","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nsmb.3400","volume":"24","author":"A Kumar","year":"2017","unstructured":"Kumar, A. et al. Parkin-phosphoubiquitin complex reveals cryptic ubiquitin-binding site required for RBR ligase activity. Nat. Struct. Mol. Biol. \n                           24, 475\u2013483 (2017).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"1947_CR44","doi-asserted-by":"publisher","first-page":"120080","DOI":"10.1098\/rsob.120080","volume":"2","author":"C Kondapalli","year":"2012","unstructured":"Kondapalli, C. et al. PINK1 is activated by mitochondrial membrane potential depolarization and stimulates Parkin E3 ligase activity by phosphorylating Serine 65. Open Biol. \n                           2, 120080 (2012).","journal-title":"Open Biol."},{"key":"1947_CR45","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/cr.2014.79","volume":"24","author":"V Sauve","year":"2014","unstructured":"Sauve, V. & Gehring, K. Phosphorylated ubiquitin: a new shade of PINK1 in Parkin activation. Cell Res. \n                           24, 1025\u20131026 (2014).","journal-title":"Cell Res."},{"key":"1947_CR46","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1083\/jcb.201402104","volume":"205","author":"LA Kane","year":"2014","unstructured":"Kane, L. A. et al. PINK1 phosphorylates ubiquitin to activate Parkin E3 ubiquitin ligase activity. J. Cell Biol. \n                           205, 143\u2013153 (2014).","journal-title":"J. Cell Biol."},{"key":"1947_CR47","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/sj.onc.1209818","volume":"26","author":"S Paltoglou","year":"2007","unstructured":"Paltoglou, S. & Roberts, B. J. HIF-1alpha and EPAS ubiquitination mediated by the VHL tumour suppressor involves flexibility in the ubiquitination mechanism, similar to other RING E3 ligases. Oncogene \n                           26, 604\u2013609 (2007).","journal-title":"Oncogene"},{"key":"1947_CR48","doi-asserted-by":"publisher","first-page":"4298","DOI":"10.1093\/emboj\/19.16.4298","volume":"19","author":"K Tanimoto","year":"2000","unstructured":"Tanimoto, K., Makino, Y., Pereira, T. & Poellinger, L. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. The EMBO J. \n                           19, 4298\u20134309 (2000).","journal-title":"The EMBO J."},{"key":"1947_CR49","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1126\/science.aaf4405","volume":"352","author":"EB Rankin","year":"2016","unstructured":"Rankin, E. B. & Giaccia, A. J. Hypoxic control of metastasis. Science \n                           352, 175\u2013180 (2016).","journal-title":"Science"},{"key":"1947_CR50","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1038\/nm.3391","volume":"19","author":"L Wan","year":"2013","unstructured":"Wan, L., Pantel, K. & Kang, Y. Tumor metastasis: moving new biological insights into the clinic. Nat. Med. \n                           19, 1450\u20131464 (2013).","journal-title":"Nat. Med."},{"key":"1947_CR51","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1093\/jnci\/95.7.516","volume":"95","author":"EJ Yeo","year":"2003","unstructured":"Yeo, E. J. et al. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J. Natl Cancer Inst. \n                           95, 516\u2013525 (2003).","journal-title":"J. Natl Cancer Inst."},{"key":"1947_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7153","volume":"6","author":"Y Goto","year":"2015","unstructured":"Goto, Y. et al. UCHL1 provides diagnostic and antimetastatic strategies due to its deubiquitinating effect on HIF-1alpha. Nat. Commun. \n                           6, 6153 (2015).","journal-title":"Nat. Commun."},{"key":"1947_CR53","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1038\/onc.2012.356","volume":"32","author":"C Zhen","year":"2013","unstructured":"Zhen, C. et al. Gankyrin promotes breast cancer cell metastasis by regulating Rac1 activity. Oncogene \n                           32, 3452\u20133460 (2013).","journal-title":"Oncogene"},{"key":"1947_CR54","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.4161\/cc.24215","volume":"12","author":"X Sun","year":"2013","unstructured":"Sun, X. et al. Parkin deficiency contributes to pancreatic tumorigenesis by inducing spindle multipolarity and misorientation. Cell Cycle \n                           12, 1133\u20131141 (2013).","journal-title":"Cell Cycle"},{"key":"1947_CR55","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1101\/gad.283283.116","volume":"30","author":"C Zhang","year":"2016","unstructured":"Zhang, C. et al. Cullin3-KLHL25 ubiquitin ligase targets ACLY for degradation to inhibit lipid synthesis and tumor progression. Genes Dev. \n                           30, 1956\u20131970 (2016).","journal-title":"Genes Dev."},{"key":"1947_CR56","doi-asserted-by":"crossref","first-page":"e10727","DOI":"10.7554\/eLife.10727","volume":"5","author":"C Zhang","year":"2016","unstructured":"Zhang, C. et al. Glutaminase 2 is a novel negative regulator of small GTPase Rac1 and mediates p53 function in suppressing metastasis. Elife \n                           5, e10727 (2016).","journal-title":"Elife"},{"key":"1947_CR57","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/ncb1441","volume":"8","author":"L Fallon","year":"2006","unstructured":"Fallon, L. et al. A regulated interaction with the UIM protein Eps15 implicates parkin in EGF receptor trafficking and PI(3)K-Akt signalling. Nat. Cell Biol. \n                           8, 834\u2013842 (2006).","journal-title":"Nat. Cell Biol."},{"key":"1947_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/srep33019","volume":"6","author":"JL Klosowiak","year":"2016","unstructured":"Klosowiak, J. L. et al. Structural insights into Parkin substrate lysine targeting from minimal Miro substrates. Sci. Rep. \n                           6, 33019 (2016).","journal-title":"Sci. Rep."},{"key":"1947_CR59","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1242\/jcs.117564","volume":"126","author":"K Janke","year":"2013","unstructured":"Janke, K. et al. Factor inhibiting HIF-1 (FIH-1) modulates protein interactions of apoptosis-stimulating p53 binding protein 2 (ASPP2). J. Cell Sci. \n                           126, 2629\u20132640 (2013).","journal-title":"J. Cell Sci."},{"key":"1947_CR60","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1172\/JCI37617","volume":"119","author":"H Xiong","year":"2009","unstructured":"Xiong, H. et al. Parkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradation. J. Clin. Invest. \n                           119, 650\u2013660 (2009).","journal-title":"J. Clin. Invest."},{"key":"1947_CR61","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/nature05993","volume":"450","author":"W Hu","year":"2007","unstructured":"Hu, W., Feng, Z., Teresky, A. K. & Levine, A. J. p53 regulates maternal reproduction through LIF. Nature \n                           450, 721\u2013724 (2007).","journal-title":"Nature"},{"key":"1947_CR62","volume":"4","author":"T Zheng","year":"2013","unstructured":"Zheng, T. et al. Spliced MDM2 isoforms promote mutant p53 accumulation and gain-of-function in tumorigenesis. Nat. Commun. \n                           4, 2996 (2013).","journal-title":"Nat. Commun."},{"key":"1947_CR63","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1038\/cdd.2015.33","volume":"22","author":"Y Zhao","year":"2015","unstructured":"Zhao, Y. et al. Pontin, a new mutant p53-binding protein, promotes gain-of-function of mutant p53. Cell Death Differ. \n                           22, 1824\u20131836 (2015).","journal-title":"Cell Death Differ."},{"key":"1947_CR64","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1101\/gad.301564.117","volume":"31","author":"X Yue","year":"2017","unstructured":"Yue, X. et al. Gain-of-function mutant p53 activates small GTPase Rac1 through SUMOylation to promote tumor progression. Genes Dev. \n                           31, 1641\u20131654 (2017).","journal-title":"Genes Dev."},{"key":"1947_CR65","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/ncb2491","volume":"14","author":"H Liu","year":"2012","unstructured":"Liu, H. et al. MYC suppresses cancer metastasis by direct transcriptional silencing of alphav and beta3 integrin subunits. Nat. Cell Biol. \n                           14, 567\u2013574 (2012).","journal-title":"Nat. Cell Biol."},{"key":"1947_CR66","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ccr.2014.04.027","volume":"26","author":"L Wan","year":"2014","unstructured":"Wan, L. et al. MTDH-SND1 interaction is crucial for expansion and activity of tumor-initiating cells in diverse oncogene- and carcinogen-induced mammary tumors. Cancer Cell \n                           26, 92\u2013105 (2014).","journal-title":"Cancer Cell"},{"key":"1947_CR67","first-page":"497","volume":"62","author":"W Xie","year":"2002","unstructured":"Xie, W. et al. Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study. Cancer Res. \n                           62, 497\u2013505 (2002).","journal-title":"Cancer Res."},{"key":"1947_CR68","doi-asserted-by":"publisher","first-page":"8783","DOI":"10.18632\/oncotarget.7088","volume":"7","author":"C Zhang","year":"2016","unstructured":"Zhang, C. et al. microRNA-1827 represses MDM2 to positively regulate tumor suppressor p53 and suppress tumorigenesis. Oncotarget \n                           7, 8783\u20138796 (2016).","journal-title":"Oncotarget"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-017-01947-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-017-01947-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-017-01947-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T23:18:44Z","timestamp":1671751124000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-017-01947-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,28]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["1947"],"URL":"https:\/\/doi.org\/10.1038\/s41467-017-01947-w","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,28]]},"assertion":[{"value":"16 February 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1823"}}